TQC3403

**TQC3403** is Chia Tai Tianqing's dry-powder inhalation fixed-dose combination of umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol trifenatate, a long-acting beta-2 adrenergic agonist, developed as a generic alternative to Anoro for long-term maintenance treatment of chronic obstructive pulmonary disease. Umeclidinium inhibits muscarinic M3 receptor-mediated bronchoconstriction, while vilanterol activates beta-2 adrenergic receptors to relax bronchial smooth muscle, producing dual long-acting bronchodilation. A multicenter randomized phase 3 equivalence trial in moderate-to-severe COPD found TQC3403 clinically equivalent to Anoro for lung-function efficacy with comparable safety and tolerability. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/42583568/))

Other names

umeclidinium bromide + vilanterolumeclidinium bromide + vilanterol trifenatate